These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11930315)

  • 1. Response to treatment and disease progression linked to CD4+ T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection.
    Gervaix A; Nicolas J; Portales P; Posfay-Barbe K; Wyler CA; Segondy M; Avinens O; Siegrist CA; Clot J; Eliaou JF; Astruc J; Corbeau P
    J Infect Dis; 2002 Apr; 185(8):1055-61. PubMed ID: 11930315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.
    Reynes J; Portales P; Segondy M; Baillat V; André P; Réant B; Avinens O; Couderc G; Benkirane M; Clot J; Eliaou JF; Corbeau P
    J Infect Dis; 2000 Mar; 181(3):927-32. PubMed ID: 10720514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast milk CD4+ T cells express high levels of C chemokine receptor 5 and CXC chemokine receptor 4 and are preserved in HIV-infected mothers receiving highly active antiretroviral therapy.
    Kourtis AP; Ibegbu CC; Theiler R; Xu YX; Bansil P; Jamieson DJ; Lindsay M; Butera S; Duerr A
    J Infect Dis; 2007 Apr; 195(7):965-72. PubMed ID: 17330786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques.
    Monceaux V; Viollet L; Petit F; Cumont MC; Kaufmann GR; Aubertin AM; Hurtrel B; Silvestri G; Estaquier J
    J Virol; 2007 Dec; 81(24):13865-75. PubMed ID: 17898067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children.
    Ometto L; Bertorelle R; Mainardi M; Zanchetta M; Tognazzo S; Rampon O; Ruga E; Chieco-Bianchi L; De Rossi A
    J Infect Dis; 2001 Mar; 183(5):814-8. PubMed ID: 11181160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.
    Mangano A; Gonzalez E; Dhanda R; Catano G; Bamshad M; Bock A; Duggirala R; Williams K; Mummidi S; Clark RA; Ahuja SS; Dolan MJ; Bologna R; Sen L; Ahuja SK
    J Infect Dis; 2001 Jun; 183(11):1574-85. PubMed ID: 11335892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.
    Lin YL; Mettling C; Portalès P; Réant B; Robert-Hebmann V; Reynes J; Clot J; Corbeau P
    AIDS; 2006 Jun; 20(10):1369-77. PubMed ID: 16791011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vitamins, including vitamin A, on HIV/AIDS patients.
    Mehta S; Fawzi W
    Vitam Horm; 2007; 75():355-83. PubMed ID: 17368322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
    Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection.
    Soares R; Foxall R; Albuquerque A; Cortesão C; Garcia M; Victorino RM; Sousa AE
    J Virol; 2006 Dec; 80(24):12425-9. PubMed ID: 17035326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Coreceptors CCR5 and CXCR4 expressions on peripheral blood T lymphocytes in HIV/AIDS patients].
    Zhao W; Wu YW; Liu W; Yao WH; Zhao H
    Zhonghua Nan Ke Xue; 2005 Aug; 11(8):574-6, 580. PubMed ID: 16138573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
    Wit FW; van Rij RP; Weverling GJ; Lange JM; Schuitemaker H
    J Infect Dis; 2002 Dec; 186(12):1726-32. PubMed ID: 12447757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection.
    Singh KK; Barroga CF; Hughes MD; Chen J; Raskino C; McKinney RE; Spector SA
    J Infect Dis; 2003 Nov; 188(10):1461-72. PubMed ID: 14624371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the stromal cell-derived factor 1 3'A mutation in pediatric human immunodeficiency virus type 1 infection.
    Tresoldi E; Romiti ML; Boniotto M; Crovella S; Salvatori F; Palomba E; Pastore A; Cancrini C; de Martino M; Plebani A; Castelli G; Rossi P; Tovo PA; Amoroso A; Scarlatti G; ;
    J Infect Dis; 2002 Mar; 185(5):696-700. PubMed ID: 11865429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
    Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
    J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The strength of the chemotactic response to a CCR5 binding chemokine is determined by the level of cell surface CCR5 density.
    Desmetz C; Lin YL; Mettling C; Portalès P; Rabesandratana H; Clot J; Corbeau P
    Immunology; 2006 Dec; 119(4):551-61. PubMed ID: 17177831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.
    Gondois-Rey F; Biancotto A; Fernandez MA; Bettendroffer L; Blazkova J; Trejbalova K; Pion M; Hirsch I
    J Virol; 2006 Jan; 80(2):854-65. PubMed ID: 16378987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T cell surface CCR5 density and virus load in persons infected with human immunodeficiency virus type 1.
    Marmor M; Krowka J; Goldberg JD
    J Infect Dis; 2000 Oct; 182(4):1284-6. PubMed ID: 10979936
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.